Search research articles
Contact Us
Filters
Showing results (511-520 of 555) with videos related to
Page
of 56
Sort By:
Cancer Communications (London, England)
|
March 16, 2026
IMMUNOSARC II Master Trial: Phase II Study of Sunitinib and Nivolumab in Clear Cell Sarcoma Cohort
Javier Martin-Broto, Sandra J Strauss, Emanuela Palmerini, et al.
Annals of Surgical Oncology
|
April 17, 2026
First-in-Human Study of CEB-01: Novel Loco-Regional SN-38-Releasing Membrane to Prevent Local Recurrence in Retroperitoneal Sarcomas
José Antonio Gonzalez, Ana Sebio, Javier Martin-Broto, et al.
Cancer Medicine
|
March 13, 2021
Systemic therapies in advanced epithelioid haemangioendothelioma: A retrospective international case series from the World Sarcoma Network and a review of literature
Anna M Frezza, Vinod Ravi, Salvatore Lo Vullo, et al.
The Lancet. Oncology
|
December 23, 2018
Pazopanib for treatment of advanced malignant and dedifferentiated solitary fibrous tumour: a multicentre, single-arm, phase 2 trial
Javier Martin-Broto, Silvia Stacchiotti, Antonio Lopez-Pousa, et al.
The Lancet. Oncology
|
July 24, 2019
Pazopanib for treatment of advanced extraskeletal myxoid chondrosarcoma: a multicentre, single-arm, phase 2 trial
Silvia Stacchiotti, Stefano Ferrari, Andres Redondo, et al.
Cancer
|
October 13, 2021
Neoadjuvant chemotherapy in high-risk soft tissue sarcomas: A Sarculator-based risk stratification analysis of the ISG-STS 1001 randomized trial
Sandro Pasquali, Emanuela Palmerini, Vittorio Quagliuolo, et al.
Lancet (London, England)
|
June 6, 2024
Vimseltinib versus placebo for tenosynovial giant cell tumour (MOTION): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
Hans Gelderblom, Vivek Bhadri, Silvia Stacchiotti, et al.
Molecular Cancer Therapeutics
|
September 23, 2021
Predictive Value of MRP-1 in Localized High-Risk Soft Tissue Sarcomas: A Translational Research Associated to ISG-STS 1001 Randomized Phase III Trial
Javier Martin-Broto, Maria Lopez-Alvarez, David S Moura, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 18, 2025
Is There a Role for Mifamurtide in Nonmetastatic High-Grade Osteosarcoma? Results From the Italian Sarcoma Group (ISG/OS-2) and Spanish Sarcoma Group (GEIS-33) Trials
Emanuela Palmerini, Cristina Meazza, Angela Tamburini, et al.
European Journal of Cancer (Oxford, England : 1990)
|
August 14, 2024
Prognostic impact of tumor location and gene expression profile in sporadic desmoid tumor
Jaime Carrillo-García, Nadia Hindi, Magda Conceicao, et al.
Page
of 56
Search research articles
Search
Showing results (511-520 of 555) with videos related to
Sort By:
Page
of 56
Cancer Communications (London, England)
|
March 16, 2026
IMMUNOSARC II Master Trial: Phase II Study of Sunitinib and Nivolumab in Clear Cell Sarcoma Cohort
Javier Martin-Broto, Sandra J Strauss, Emanuela Palmerini, et al.
Annals of Surgical Oncology
|
April 17, 2026
First-in-Human Study of CEB-01: Novel Loco-Regional SN-38-Releasing Membrane to Prevent Local Recurrence in Retroperitoneal Sarcomas
José Antonio Gonzalez, Ana Sebio, Javier Martin-Broto, et al.
Cancer Medicine
|
March 13, 2021
Systemic therapies in advanced epithelioid haemangioendothelioma: A retrospective international case series from the World Sarcoma Network and a review of literature
Anna M Frezza, Vinod Ravi, Salvatore Lo Vullo, et al.
The Lancet. Oncology
|
December 23, 2018
Pazopanib for treatment of advanced malignant and dedifferentiated solitary fibrous tumour: a multicentre, single-arm, phase 2 trial
Javier Martin-Broto, Silvia Stacchiotti, Antonio Lopez-Pousa, et al.
The Lancet. Oncology
|
July 24, 2019
Pazopanib for treatment of advanced extraskeletal myxoid chondrosarcoma: a multicentre, single-arm, phase 2 trial
Silvia Stacchiotti, Stefano Ferrari, Andres Redondo, et al.
Cancer
|
October 13, 2021
Neoadjuvant chemotherapy in high-risk soft tissue sarcomas: A Sarculator-based risk stratification analysis of the ISG-STS 1001 randomized trial
Sandro Pasquali, Emanuela Palmerini, Vittorio Quagliuolo, et al.
Lancet (London, England)
|
June 6, 2024
Vimseltinib versus placebo for tenosynovial giant cell tumour (MOTION): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
Hans Gelderblom, Vivek Bhadri, Silvia Stacchiotti, et al.
Molecular Cancer Therapeutics
|
September 23, 2021
Predictive Value of MRP-1 in Localized High-Risk Soft Tissue Sarcomas: A Translational Research Associated to ISG-STS 1001 Randomized Phase III Trial
Javier Martin-Broto, Maria Lopez-Alvarez, David S Moura, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 18, 2025
Is There a Role for Mifamurtide in Nonmetastatic High-Grade Osteosarcoma? Results From the Italian Sarcoma Group (ISG/OS-2) and Spanish Sarcoma Group (GEIS-33) Trials
Emanuela Palmerini, Cristina Meazza, Angela Tamburini, et al.
European Journal of Cancer (Oxford, England : 1990)
|
August 14, 2024
Prognostic impact of tumor location and gene expression profile in sporadic desmoid tumor
Jaime Carrillo-García, Nadia Hindi, Magda Conceicao, et al.
Page
of 56